Uncategorized
GALILEO results show visual acuity gains diminished with less frequent monitoring
SEATTLE — Visual improvements gained during the fixed dosing period of intravitreal aflibercept injection in the GALILEO trial were not sustained once an as-needed dosing regimen was implemented with reduced monitoring frequency, according to 18-month results presented here.“These results indicate a potential added benefit with earlier treatment,” Yuichiro Ogura, MD, PhD, said at the Association for Research in Vision and Ophthalmology meeting.